scholarly journals Changing Trends of Breast Cancer Survival in Sultanate of Oman

2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
Shiyam Kumar ◽  
Ikram A. Burney ◽  
Adel Al-Ajmi ◽  
Mansour S. Al-Moundhri
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Cancer Survival ◽  
Survival Rates ◽  
Breast Cancer Survival ◽  
Lymph Node Status ◽  
Skin Involvement ◽  
Sultanate Of Oman ◽  
Breast Cancer Patients ◽  
Free Survival

Breast cancer is the leading cause of cancer-associated mortality in women, with elevated incidence in developing countries. This retrospective study included all 122 patients diagnosed with breast cancer from January 2003 to December 2008 in the Sultanate of Oman. Age at presentation was 47.41 years (SD12.88), with one-third of patients younger than 40 years. The majority of patients presented with stage III (41.2%) and IV (18.2%) breast cancer. T size (), skin involvement (), and stage at presentation () were significantly associated with overall survival. Skin involvement at presentation (), T size (), lymph node status (), and stage () were strong predictors of relapse-free survival. Patients had a 5-year survival of 78%, compared to 64% of breast cancer patients diagnosed between 1996 and 2002 identified in our previously published study. Thus, despite Omani breast cancer patients continuing to present with advanced breast cancer, survival rates have significantly improved.

Young Age is not an Ominous Prognostic Factor in Breast Cancer Patients

1987 ◽  
Vol 73 (3) ◽  
pp. 233-235 ◽  
Author(s):  
Giuseppe Muscolino ◽  
Corrado Villani ◽  
Amedeo Vittorio Bedini ◽  
Alberto Luini ◽  
Bruno Salvadori
Keyword(s):  
Breast Cancer ◽  
Prognostic Factor ◽  
Cancer Patients ◽  
Young Women ◽  
Survival Rates ◽  
Disease Free Survival ◽  
Young Age ◽  
Breast Cancer Patients ◽  
Free Survival ◽  
Disease Free

Analysis of a series of 137 women 20–30 years of age, operated for breast carcinoma, excluding patients pregnant, lactating or with inflammatory cancer, showed that disease-free survival rates were similar and not lower than those reported for a large series of 716 breast cancer patients of all ages, treated and followed at the same Institute. Ten-year disease-free survival rates for the two series of 137 young women and 716 patients of all ages were 43.7% and 47.1% respectively. Even when considering the subgroups of patients with and without nodal axillary involvement, the corresponding figures for the two series considered were 72.6% vs. 72.1% (N−) and 25.1% vs. 24.5% (N+). It can be concluded that young age cannot be considered as an unfavorable prognostic factor.

Breast-conserving surgery after neoadjuvant chemotherapy for stage III breast cancer patients.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e11532-e11532
Author(s):  
Hee-Chul Shin ◽  
Wonshik Han ◽  
Hyeong-Gon Moon ◽  
Woo Kyung Moon ◽  
Seock-Ah Im ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Clinical Stage ◽  
Survival Rates ◽  
Disease Free Survival ◽  
Stage Iii ◽  
Breast Cancer Patients ◽  
Free Survival ◽  
Stage Iii Breast Cancer

e11532 Background: Neoadjuvant chemotherapy (NCT) is a reasonable option for operable breast cancer in terms of downsizing large tumor and increasing the rate of breast-conserving surgery (BCS). However, BCS in patients with large breast tumors down-staged by NCT remains still controversial because of the possibility of residual tumor and resistance to NCT. Aims of this study were to evaluate the long-term survival results of patients who received NCT and BCS compared to patients who received BCS first and to compare recurrence and survival rates between patients who received preplanned BCS and those who received down-staged BCS among patients who underwent NCT. Methods: Between 2000 and 2007, 70 patients with clinical stage III breast cancer who received BCS after NCT (NCT group) and 72 patients with clinical stage III breast cancer who underwent BCS first (Surgery group) were retrospectively reviewed. Among 70 patients received NCT, 45 patients (64.3%) received preplanned BCS (preplanned BCS group) and 25 patients (35.7%) received down-staged BCS (down-staged BCS group). The long-term results including ipsilateral breast tumor recurrence (IBTR), locoregional recurrence (LRR), disease recurrence and survival rates were compared with groups. Results: There was no significant difference in IBTR-free survival, LRR-free survival rates, disease-free survival and overall survival rates between the NCT and the Surgery group (p=0.971, p=0.294, p=0.863 and p=0.933, respectively). Among patients who received NCT, IBTR-free survival, LRR-free survival, disease-free survival and overall survival rates was not also different between the preplanned BCS group and the down-staged BCS group (p=0.278, p=0.501, p=0.776 and p=0.412, respectively). Conclusions: Our study demonstrated that patients who received BCS after NCT showed similar long-term resutls compared to patients who received BCS first in clinical stage III breast cancer patients. Also, down-staged BCS shows is oncologically as safe as preplanned BCS in clinical stage III breast cancer patients in terms of recurrence and survival.

scholarly journals Comparison of Breast Cancer 3-years Survival Rate Based on the Pathological Stages

2019 ◽  
Vol 10 (1) ◽  
pp. 38
Author(s):  
Nur Imroatul Mursyidah ◽  
Ami Ashariati ◽  
Etty Hary Kusumastuti
Keyword(s):  
Breast Cancer ◽  
Survival Rate ◽  
Cancer Patients ◽  
General Hospital ◽  
Cancer Survival ◽  
Stage Iv ◽  
Secondary Data ◽  
Breast Cancer Survival ◽  
Breast Cancer Patients ◽  
Retrospective Case

ABSTRACTIntroduction: The aims of this study was to determine the differences of  breast cancer survival rate based on Pathological stages.Methods: This study was conducted with a retrospective case control design using secondary data from Dr. Soetomo General Hospital's medical records. The technique used to take the samples was purposive sampling. The sample was 45 breast cancer patients in Dr. Soetomo General Hospital In January 2015, that able to be contacted again and had a medical record in the oncology center in Dr. Soetomo General Hospital Surabaya. The variables studied is breast cancer survival based on the pathological stages.Results: Breast cancer patients at the stage of IIA have 100% 3-year survival rate, stage IIB by 83.3%, stage IIIA by 71.4%, stage IIIB by 53.8%, IIIC by 50%, and stage IV by 30%. With a comparison of the log-rank significance p = 0.104.Conclusion: The survival rate of breast cancer patients is lower in line with the increasing pathological stage of breast cancer.

scholarly journals Serum Selenium Level Predicts 10-Year Survival after Breast Cancer

Nutrients ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 953
Author(s):  
Marek Szwiec ◽  
Wojciech Marciniak ◽  
Róża Derkacz ◽  
Tomasz Huzarski ◽  
Jacek Gronwald ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Cancer Survival ◽  
Survival Rates ◽  
Selenium Level ◽  
Serum Selenium ◽  
Breast Cancer Patients ◽  
Serum Selenium Levels ◽  
Serum Selenium Level

In a recent prospective study, we reported an association between a low serum selenium level and five-year survival among breast cancer patients. We now have updated the cohort to include 10-year survival rates. A blood sample was obtained from 538 women diagnosed with first primary invasive breast cancer between 2008 and 2015 in the region of Szczecin, Poland. Blood was collected before initiation of treatment. Serum selenium levels were quantified by mass spectroscopy. Each patient was assigned to one of four quartiles based on the distribution of serum selenium levels in the whole cohort. Patients were followed from diagnosis until death or last known alive (mean follow-up 7.9 years). The 10-year actuarial cumulative survival was 65.1% for women in the lowest quartile of serum selenium, compared to 86.7% for women in the highest quartile (p < 0.001 for difference). Further studies are needed to confirm the protective effect of selenium on breast cancer survival. If confirmed this may lead to an investigation of selenium supplementation on survival of breast cancer patients.

scholarly journals Survival of Women With Breast Cancer in Kaunas Region, Lithuania

Medicina ◽  
2012 ◽  
Vol 48 (5) ◽  
pp. 39 ◽  
Author(s):  
Rugilė Ivanauskienė ◽  
Jurgita Gedminaitė ◽  
Elona Juozaitytė ◽  
Giedrius Vanagas ◽  
Renata Šimoliūnienė ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Survival ◽  
Survival Rates ◽  
Breast Cancer Survival ◽  
European Countries ◽  
Disease Stage ◽  
Breast Cancer Patients ◽  
Kaplan Meier ◽  
Cox Proportional Hazard Models ◽  
Advanced Disease Stage

Objective. The assessment of breast cancer survival rates and comparison with those of other countries may help to deepen knowledge among decision makers in the health care system and to improve the inequalities in accessibility to early detection and effective treatment. The aim of this study was to evaluate breast cancer survival rates in Kaunas region, Lithuania, and to compare them with those in the selected European countries. Material and Methods. A retrospective study was carried out using medical records and data gathered from the Lithuanian Cancer Registry. A group of 240 patients with primary breast cancer diagnosed in 2008 in Kaunas region was analyzed. All causes of death were included in the analysis. The closing date of follow-up was September 30, 2010. Survival was determined using the life-table method and the Kaplan-Meier method. Cox proportional hazard models were used to estimate the effects of prognostic risk factors on survival. Results. The median age of the patients was 63 years (range, 28–95). The 1-year and 2-year cumulative survival for breast cancer patients in Kaunas region, Lithuania, was 94.2% and 90.1%, respectively. As expected, the survival of patients with diagnosed advanced disease (stage III and IV) was significantly worse than that of patients with stage I (P<0.001) and II (P=0.003) disease. The screening group (aged 50–69 years) showed better survival in comparison with the group older than 69 years. Age, T4 tumor, and distant metastasis were the prognostic factors significantly associated with an increased relative mortality risk of breast cancer. Conclusions. Compared to the European survival rates, the 1-year and 2-year survival of patients with breast cancer in Lithuania was found to be similar to most European countries.

scholarly journals The variant T allele of PvuII in ESR1 gene is a prognostic marker in early breast cancer survival

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Danny Houtsma ◽  
Stefanie de Groot ◽  
Renee Baak-Pablo ◽  
Elma Meershoek -Klein Kranenbarg ◽  
Caroline M. Seynaeve ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Prognostic Marker ◽  
Early Breast Cancer ◽  
Cancer Survival ◽  
Breast Cancer Survival ◽  
Breast Cancer Patients ◽  
Available N ◽  
Cox Regression Analysis ◽  
Breast Cancer Outcome

AbstractThe PvuII (rs2234693) Single Nucleotide Polymorphism (SNP) in the gene coding for the estrogen receptor-1 (ESR1), has been found associated with outcome in tamoxifen treated patients with early hormone-receptor positive breast cancer. However, it remains unclear whether this SNP is a predictive marker for tamoxifen efficacy or a prognostic marker for breast cancer outcome. The aim of this study was to examine the prognostic potential of this SNP in postmenopausal early breast cancer patients treated with adjuvant exemestane. Dutch postmenopausal patients randomised to 5 years of adjuvant exemestane of whom tissue was available (N = 807) were selected from the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial database. The SNP rs2234693 in the ESR1 gene was genotyped on DNA from formalin-fixed paraffin embedded (FFPE) tumor tissue using Taqman assays and related to the primary endpoint disease-free survival (DFS) and secondary endpoint overall survival (OS). Survival analyses were performed using Cox regression analysis. In total 805 patients were included in the analyses (median follow up of 5.22 years) and genotypes were obtained in 97% of the samples. The variant T allele of PvuII in ESR1 (rs2234693) was associated with a better DFS (hazard ratio (HR) 0.689, 95% confidence interval (CI) 0.480–0.989, P = 0.044) in univariate analysis only, and a better OS in both univariate (HR 0.616, 95%, CI 0.411–0.923, P = 0.019) and multivariate analyses (HR 0.571, 95% CI 0.380–0.856, P = 0.007), consistent with a prognostic rather than a predictive drug response effect. Variation of PvuII in the ESR1 gene is related to OS in postmenopausal, early HR + breast cancer patients treated with exemestane in the TEAM study. Variation in the ESR1 gene may therefore be a prognostic marker of early breast cancer survival, and warrants further research.

Breast Cancer Patients with Progesterone Receptor PR-A-Rich Tumors Have Poorer Disease-Free Survival Rates

2004 ◽  
Vol 10 (8) ◽  
pp. 2751-2760 ◽  
Author(s):  
Torsten A. Hopp ◽  
Heidi L. Weiss ◽  
Susan G. Hilsenbeck ◽  
Yukun Cui ◽  
D. Craig Allred ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Progesterone Receptor ◽  
Cancer Patients ◽  
Survival Rates ◽  
Disease Free Survival ◽  
Breast Cancer Patients ◽  
Free Survival ◽  
Disease Free

Estimating Relative Survival of Italian Cancer Patients from Sparse Cancer Registries Data

1997 ◽  
Vol 83 (1) ◽  
pp. 33-38 ◽  
Author(s):  
Roberta De Angelis ◽  
Riccardo Capocaccia ◽  
Arduino Verdecchia
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Survival Data ◽  
Cancer Survival ◽  
National Level ◽  
Survival Rates ◽  
Relative Survival ◽  
Cancer Registries ◽  
Breast Cancer Patients ◽  
National Estimates

Purpose A method is presented for estimating relative survival of cancer patients at the national level from survival data provided by cancer registries covering only a subset of the general population and referring to different, and not necessarily overlapping, incidence periods. Methods Relative survival rates are estimated as a function of the covariates sex, age, epoch of diagnosis, and registry area by means of a multiple regression model. National estimates are then computed by appropriate weighting of the sex-, age-, time- and registry-specific expected relative survival values. Results The method is illustrated by a sample application to survival data of female breast cancer patients in Italy. The national estimates of breast cancer survival pattern show a mild decrease of survival with age and a marked increase with period of diagnosis.

Effect of Wnt5a on aggressiveness of ER-positive breast cancer and cancer cell migration through JNK-ALCAM pathway.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 11614-11614
Author(s):  
Yoshie Kobayashi ◽  
Takayuki Kadoya ◽  
Ai Amioka ◽  
Noriko Gohda ◽  
Miho Kono ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Survival Rates ◽  
Breast Cancer Patients ◽  
Mcf7 Cells ◽  
Relapse Free Survival ◽  
Free Survival ◽  
Wnt5a Expression ◽  
Er Positive ◽  
Positive Breast Cancer

11614 Background: Wnt5a is a representative ligand that activates β-catenin-independent pathways and involved in cell motility and cell polarity, and the like, being mediated by JNK. We elucidated the implication of Wnt5a expression in breast cancer. Methods: One hundred seventy eight breast cancer patients (mean age ± SD: 60.0 ± 13.2 years) with clinical Stage I-III between January 2011 and February 2014, were prospectively evaluated. We examined relationships between Wnt5a expression and clinicopathological factors by immunohistochemical analyses. 5-year relapse-free survival rates and sites of recurrence were analyzed. In addition, molecules induced by Wnt5a in cultured cells were identified by DNA microarray analysis. Results: Wnt5a expression was significantly more frequent when estrogen receptor (ER) was present, 68/153 (44%) than when ER was absent, 1/25 (4%) (P <0.001) (Table). In ER-positive breast cancer, a significant interaction between expression of Wnt5a with lymph node metastasis (P<0.001), high nuclear grade (P=0.004), and lymphatic invasion (P=0.001). 5-year relapse-free survival rates were 81.1% and 100% in Wnt5a-positive and Wnt5a-negative breast cancers, respectively (P = 0.024). All recurrent breast cancer patients in this study had bone metastasis. We established MCF7 stably expressing Wnt5a (Wnt5a/MCF7 cells) and microarray analyses identified several genes induced by Wnt5a (>3.0 fold), involving activated leukocyte cell adhesion molecule (ALCAM). ALCAM is known to be related with apoptosis, invasion and prognosis of breast cancer. We focused on ALCAM and investigated its protein expression by Western blotting, and found remarkable increase of ALCAM in Wnt5a/MCF7 cells. Conclusions: Wnt5a expresses in ER-positive breast cancer and is associated with high-grade malignancy and a poor prognosis through JNK-ALCAM pathway. Wnt5a could be a novel prognostic factor of ER-positive breast cancer. [Table: see text]

scholarly journals Abnormal Long Non-Coding RNAs Expression Patterns Have the Potential Ability for Predicting Survival and Treatment Response in Breast Cancer

Genes ◽  
2021 ◽  
Vol 12 (7) ◽  
pp. 996
Author(s):  
Ana Carolina Pavanelli ◽  
Flavia Rotea Mangone ◽  
Luciana R. C. Barros ◽  
Juliana Machado-Rugolo ◽  
Vera L. Capelozzi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Predictive Value ◽  
Expression Patterns ◽  
Survival Rates ◽  
In Silico Analysis ◽  
Cancer Prognosis ◽  
Response To Treatment ◽  
Breast Cancer Patients ◽  
Non Coding Rnas

Abnormal long non-coding RNAs (lncRNAs) expression has been documented to have oncogene or tumor suppressor functions in the development and progression of cancer, emerging as promising independent biomarkers for molecular cancer stratification and patients’ prognosis. Examining the relationship between lncRNAs and the survival rates in malignancies creates new scenarios for precision medicine and targeted therapy. Breast cancer (BRCA) is a heterogeneous malignancy. Despite advances in its molecular classification, there are still gaps to explain in its multifaceted presentations and a substantial lack of biomarkers that can better predict patients’ prognosis in response to different therapeutic strategies. Here, we performed a re-analysis of gene expression data generated using cDNA microarrays in a previous study of our group, aiming to identify differentially expressed lncRNAs (DELncRNAs) with a potential predictive value for response to treatment with taxanes in breast cancer patients. Results revealed 157 DELncRNAs (90 up- and 67 down-regulated). We validated these new biomarkers as having prognostic and predictive value for breast cancer using in silico analysis in public databases. Data from TCGA showed that compared to normal tissue, MIAT was up-regulated, while KCNQ1OT1, LOC100270804, and FLJ10038 were down-regulated in breast tumor tissues. KCNQ1OT1, LOC100270804, and FLJ10038 median levels were found to be significantly higher in the luminal subtype. The ROC plotter platform results showed that reduced expression of these three DElncRNAs was associated with breast cancer patients who did not respond to taxane treatment. Kaplan–Meier survival analysis revealed that a lower expression of the selected lncRNAs was significantly associated with worse relapse-free survival (RFS) in breast cancer patients. Further validation of the expression of these DELncRNAs might be helpful to better tailor breast cancer prognosis and treatment.

Sign in / Sign up

Export Citation Format

Share Document